AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- Mayo Clinic researchers found that dehydroepiandrosterone (DHEA) significantly increased insulin-mediated glucose disposal in a group of hypoadrenal women.
The finding led them to question the need for DHEA in this patient population.
"Dehydroepiandrosterone and its sulfated ester (DHEAS) are the most abundant circulating steroid hormones. Their physiological function has yet to be determined. Hypoadrenal subjects lack this hormone because DHEA replacement is not part of the current standard of care. There are conflicting reports on the impact of DHEA replacement in hypoadrenal subjects on insulin sensitivity," said K. Dhatariya and colleagues with the Mayo Clinic's Endocrine Research Unit in Rochester, Minnesota, U.S.
They conducted a study to study this and to "examine skeletal muscle physiology using a hyperinsulinemic euglycemic clamp after 12 weeks of DHEA and placebo" in a randomized, double-blind, placebo-controlled, crossover study.
The study group - 33 hypoadrenal women ([+ or -]SD) (mean age 49.7 [+ or -] 15.6 years) - received either DHEA 50 mg or placebo in a single daily dose.
"After 12 weeks body composition was assessed by DEXA and insulin sensitivity was assessed," according to the researchers.
They found no differences in body composition. "Fasting plasma insulin and glucagon were lower with DHEA (7.07 [+ or -] 4.35 vs. 8.88 [+ or -] 5.81 microU/ml, p=0.003; and 177.7 [+ or -] 59.9 vs. 195.04 [+ or -] 79.5 pg/ml, p=0.038, respectively)," Dhatariya's group reported.
Source: HighBeam Research, DHEA increases insulin-mediated glucose disposal in hypoadrenal women.